- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04718896
A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis (BE CONNECTED)
A Multicenter, Open-Label, Randomized Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Calgary, Canada
- Ps0020 50354
-
St. John's, Canada
- Ps0020 50357
-
-
-
-
-
Frankfurt, Germany
- Ps0020 40645
-
-
-
-
-
Bialystok, Poland
- Ps0020 40626
-
Lodz, Poland
- Ps0020 40625
-
Rzeszow, Poland
- Ps0020 40396
-
Warszawa, Poland
- Ps0020 40335
-
Wroclaw, Poland
- Ps0020 40333
-
Wroclaw, Poland
- Ps0020 40334
-
-
-
-
Indiana
-
Indianapolis, Indiana, United States, 46250
- Ps0020 50344
-
-
Texas
-
Cypress, Texas, United States, 77433
- Ps0020 50359
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participant must be ≥12 to less than 18 years of age at the time of signing the informed consent/assent according to local regulation
Participant has had a diagnosis of moderate to severe plaque psoriasis (PSO) for at least 3 months prior to the Screening Visit and:
- Body surface area (BSA) affected by PSO ≥10%
- Investigator's Global Assessment (IGA) score ≥3 (on a scale from 0 to 4)
- Psoriasis Area and Severity Index (PASI) score ≥12 OR
- PASI score ≥10 plus at least 1 of the following:
i. Clinically relevant facial involvement ii. Clinically relevant genital involvement iii. Clinically relevant hand and foot involvement
- Participant must be candidate for systemic PSO therapy and/or photo/chemotherapy
- Body weight ≥30 kg and body mass index for age percentile of ≥5 at Baseline
- Male or female A female participant will be eligible to participate if she is not pregnant, not breastfeeding, and a woman of childbearing potential (WOCBP) agrees to follow the contraceptive guidance
- Capable of giving/having parent(s) or legal representative provide signed informed consent/assent (where appropriate)
Exclusion Criteria:
- Participant has a presence of guttate, inverse, pustular, or erythrodermic PSO or other dermatological condition that may impact the clinical assessment of PSO
- Participant has a history of inflammatory bowel disease (IBD) or symptoms suggestive of IBD
- History of active tuberculosis unless successfully treated, latent TB unless prophylactically treated
- Participant has an active infection or history of infections (such as serious infection, chronic infections, opportunistic infections, unusually severe infections)
- Participant has laboratory abnormalities at Screening
- Participant has experienced primary failure to one or more interleukin-17 (IL-17) biologic response modifier OR primary failure to more than 1 biologic response modifier other than an IL-17 biologic response modifier
- Presence of active suicidal ideation, or positive suicide behavior
- Participant has been diagnosed with severe depression in the past 6 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bimekizumab Dose A
Study participants randomized to this arm will receive bimekizumab (BKZ) Dose A at pre-specified time points during the study.
|
Study participants will receive subcutaneously administered bimekizumab (BKZ) at pre-specified time points during the study.
Other Names:
|
Experimental: Bimekizumab Dose B
Study participants randomized to this arm will receive bimekizumab (BKZ) Dose B at pre-specified time points during the study.
|
Study participants will receive subcutaneously administered bimekizumab (BKZ) at pre-specified time points during the study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma concentration of bimekizumab at Week 0
Time Frame: Baseline (Week 0)
|
Blood samples will be collected at pre-specified time points to determine the bimekizumab plasma concentration at Week 0.
|
Baseline (Week 0)
|
Plasma concentration of bimekizumab at Week 1
Time Frame: Week 1
|
Blood samples will be collected at pre-specified time points to determine the bimekizumab plasma concentration at Week 1.
|
Week 1
|
Plasma concentration of bimekizumab at Week 4
Time Frame: Week 4
|
Blood samples will be collected at pre-specified time points to determine the bimekizumab plasma concentration at Week 4.
|
Week 4
|
Plasma concentration of bimekizumab at Week 8
Time Frame: Week 8
|
Blood samples will be collected at pre-specified time points to determine the bimekizumab plasma concentration at Week 8.
|
Week 8
|
Plasma concentration of bimekizumab at Week 12
Time Frame: Week 12
|
Blood samples will be collected at pre-specified time points to determine the bimekizumab plasma concentration at Week 12.
|
Week 12
|
Plasma concentration of bimekizumab at Week 16
Time Frame: Week 16
|
Blood samples will be collected at pre-specified time points to determine the bimekizumab plasma concentration at Week 16.
|
Week 16
|
Plasma concentration of bimekizumab at Week 20
Time Frame: Week 20
|
Blood samples will be collected at pre-specified time points to determine the bimekizumab plasma concentration at Week 20.
|
Week 20
|
Plasma concentration of bimekizumab at Week 36
Time Frame: Week 36
|
Blood samples will be collected at pre-specified time points at Week 36 to determine the bimekizumab plasma concentration, if participant is not eligible for the Open-label Extension (OLE) Period at Week 20 or does not wish to continue into the OLE Period.
|
Week 36
|
Plasma concentration of bimekizumab at Week 40
Time Frame: Week 40
|
Blood samples will be collected at pre-specified time points to determine the bimekizumab plasma concentration at Week 40.
|
Week 40
|
Plasma concentration of bimekizumab at Week 64
Time Frame: Week 64
|
Blood samples will be collected at pre-specified time points to determine the bimekizumab plasma concentration at Week 64.
|
Week 64
|
Plasma concentration of bimekizumab at Week 88
Time Frame: Week 88
|
Blood samples will be collected at pre-specified time points to determine the bimekizumab plasma concentration at Week 88.
|
Week 88
|
Plasma concentration of bimekizumab at Week 112
Time Frame: Week 112
|
Blood samples will be collected at pre-specified time points to determine the bimekizumab plasma concentration at Week 112.
|
Week 112
|
Plasma concentration of bimekizumab at Week 124
Time Frame: Week 124
|
Blood samples will be collected at pre-specified time points to determine the bimekizumab plasma concentration at Week 124.
|
Week 124
|
Plasma concentration of bimekizumab at safety follow up (SFU)
Time Frame: Week 140 (SFU)
|
Blood samples will be collected at pre-specified time points to determine the bimekizumab plasma concentration at Week 140 (SFU).
|
Week 140 (SFU)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of participants with treatment-emergent adverse events (TEAEs)
Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)]
|
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.
Treatment-emergent AEs are defined as those AEs that have a start date on or following the first dose of IMP through the final dose of IMP + 20 weeks.
|
From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)]
|
Percentage of participants with serious TEAEs
Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
An serious adverse event (SAE) must meet 1 or more of the following criteria:
Treatment-emergent AEs are defined as those AEs that have a start date on or following the first dose of IMP through the final dose of IMP + 20 weeks. |
From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Percentage of participants with TEAEs leading to discontinuation of investigational medicinal product (IMP)
Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.
Treatment-emergent AEs are defined as those AEs that have a start date on or following the first dose of IMP through the final dose of IMP + 20 weeks.
This measure considers any TEAE leading to permanent discontinuation of IMP regardless of reason.
|
From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Percentage of participants with selected safety topics of interest
Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Selected safety topics of interest (including infection [serious, opportunistic, fungal, and tuberculosis (TB)], inflammatory bowel disease [IBD], and injection site reactions) with onset occurring from day of first dose through 20 weeks after final dose of IMP adjusted by duration of participant exposure to IMP.
|
From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Change from Baseline in vital signs (systolic and diastolic blood pressure)
Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Blood pressure will be measured in millimeters of mercury (mmHg).
|
From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Change from Baseline in vital signs (heart rate or pulse rate)
Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Heart rate will be measured in beats per minute (beats/min).
|
From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Change from Baseline in vital signs (temperature)
Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Temperature (oral, axillary, otic or non-contact forehead) will be measured in degrees Celsius (°C).
|
From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Change from Baseline in physical examination findings reported as TEAEs with onset occurring from day of first dose through 20 weeks after final dose of IMP
Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Clinically significant findings or worsening of previous findings since the physical examination at Baseline will be reported as TEAEs with onset occurring from day of first dose through 20 weeks after final dose of IMP.
|
From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Change from Baseline in hematology parameters (platelet count)
Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Platelets will be measured in number of platelets per liter (10^9/L).
|
From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Change from Baseline in hematology parameters (mean corpuscular hemoglobin)
Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Mean corpuscular hemoglobin (HGB) will be measured in picograms (pg).
|
From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Change from Baseline in hematology parameters (mean corpuscular volume)
Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Mean corpuscular volume will be measured in femtolitres (fL).
|
From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Change from Baseline in hematology parameters (erythrocytes)
Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Erythrocytes will be measured in number of red blood cells per liter (10^12/L).
|
From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Change from Baseline in hematology parameters (hemoglobin)
Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Hemoglobin will be measured in grams per liter (g/L).
|
From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Change from Baseline in hematology parameters (hematocrit)
Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Hematocrit will be measured in volume percentage (%) of red blood cells in blood.
|
From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Change from Baseline in clinical chemistry parameters (alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase)
Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase will be measured in units per liter (U/L).
|
From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Change from Baseline in hematology parameters (basophils, eosinophils, lymphocytes, monocytes, neutrophils, leukocytes)
Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Basophils, eosinophils, lymphocytes, monocytes, neutrophils and leukocytes will be measured in number of white blood cells per liter (10^9/L)
|
From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Change from Baseline in clinical chemistry parameters (calcium, potassium, sodium, blood urea nitrogen, glucose (nonfasting))
Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Calcium, potassium, sodium, blood urea nitrogen, and glucose (non fasting) will be measured in millimoles per liter (mmol/L).
|
From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Change from Baseline in clinical chemistry parameters (creatinine, total and direct bilirubin)
Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Creatinine and bilirubin will be measured in micromols per liter (μmol/L).
|
From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Change from Baseline in clinical chemistry parameters (total protein)
Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Total protein will be measured in milligrams per liters (mg/L).
|
From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Change from Baseline in height
Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Growth assessment, as assessed by the change from Baseline in height.
|
From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Change from Baseline in weight
Time Frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Growth assessment, as assessed by the change from Baseline in weight.
|
From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
|
Percentage of participants with Psoriasis Area and Severity Index (PASI) 90 response at Week 16
Time Frame: Week 16
|
The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline.
This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved.
Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks.
Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked).
Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale.
Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section.
The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.
|
Week 16
|
Percentage of participants with Investigator's Global Assessment (IGA) 0/1 (Clear [0]/Almost Clear [1] with at least 2-category improvement from Baseline) response at Week 16
Time Frame: Week 16
|
The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response (Clear or Almost Clear) is defined as clear [0] or almost clear [1] with at least a two-category improvement from Baseline. |
Week 16
|
Percentage of participants with Psoriasis Area and Severity Index (PASI) 75 response at Week 4
Time Frame: Week 4
|
The PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline.
This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved.
Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks.
Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked).
Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale.
Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section.
The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.
|
Week 4
|
Percentage of participants with anti-bimekizumab antibody (AbAb) detection prior to investigational medicinal product (IMP) administration
Time Frame: Baseline (Week 0)
|
Anti-bimekizumab antibody (AbAb) detection prior to investigational medicinal product (IMP) administration
|
Baseline (Week 0)
|
Percentage of participants with anti-bimekizumab antibody (AbAb) detection following investigational medicinal product (IMP) administration
Time Frame: From Week 1 through 20 weeks after final dose of IMP (up to Week 140)
|
Anti-bimekizumab antibody (AbAb) detection following investigational medicinal product (IMP) administration
|
From Week 1 through 20 weeks after final dose of IMP (up to Week 140)
|
Change from Baseline in Children's Dermatology Life Quality Index (CDLQI) response at Week 16
Time Frame: Week 16, compared to Baseline
|
The CDLQI is a questionnaire designed to measure the impact of skin diseases on the lives of children.
The questionnaire consists of 10 questions that are based on the experiences of children with skin disease.
The instrument asks participants about symptoms and feelings, leisure, school or holidays, personal relationships, sleep, and treatment.
The questions relate to the impact of the skin disease on the child over the last week, (ie, over the last 7 days).
The CDLQI total score ranges from 0 to 30 with higher scores indicating higher impact of skin disease on quality of life (Qol).
|
Week 16, compared to Baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: UCB Cares, 001 844 599 2273
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PS0020
- 2020-001724-34 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Moderate to Severe Plaque Psoriasis
-
Idera Pharmaceuticals, Inc.CompletedModerate to Severe Plaque Psoriasis | Actively Extending Plaque PsoriasisUnited States
-
Fresenius Kabi SwissBioSim GmbHMerck KGaA, Darmstadt, GermanyCompletedPsoriasis | Moderate to Severe Plaque Psoriasis | Plaque Type PsoriasisUnited States, Canada, Czechia, Hungary, Russian Federation, Bulgaria, Mexico, United Kingdom, Poland, Germany, Estonia, France
-
UCB Biopharma SRLCompletedModerate to Severe Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Taiwan
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Canada
-
Bristol-Myers SquibbNot yet recruitingModerate-to-severe Plaque PsoriasisKorea, Republic of
-
Novartis PharmaceuticalsRecruitingModerate-to-severe Plaque PsoriasisRussian Federation
-
UCB Biopharma SRLCompletedModerate to Severe Plaque PsoriasisKorea, Republic of
-
Novartis PharmaceuticalsCompletedModerate-to-severe Plaque PsoriasisIndonesia
-
AbbVie (prior sponsor, Abbott)CompletedModerate to Severe Plaque PsoriasisGermany
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...UnknownModerate to Severe Plaque PsoriasisChina
Clinical Trials on bimekizumab
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Taiwan, United Kingdom
-
UCB Biopharma SRLCompletedPsoriatic ArthritisUnited States, Czechia, Germany, Hungary, Poland, Russian Federation
-
UCB Biopharma S.P.R.L.CompletedHealthy VolunteersUnited States, Germany
-
UCB Biopharma SRLActive, not recruitingHidradenitis SuppurativaUnited States, Australia, Belgium, Bulgaria, Canada, Czechia, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Netherlands, Poland, Spain, Switzerland, Turkey, United Kingdom
-
UCB Biopharma SRLCompletedHidradenitis SuppurativaUnited States, Australia, Bulgaria, Canada, Czechia, France, Germany, Hungary, Ireland, Israel, Japan, Poland, Spain, United Kingdom
-
UCB Biopharma SRLCompletedAnkylosing SpondylitisUnited States, Bulgaria, Canada, Czechia, Germany, Hungary, Poland, Russian Federation, Spain, Ukraine
-
UCB Biopharma SRLCompletedChronic Plaque PsoriasisUnited States, Australia, Canada, Moldova, Republic of
-
UCB Biopharma SRLCompletedPsoriatic ArthritisUnited States, Australia, Canada, Czechia, Germany, Hungary, Italy, Japan, Poland, Russian Federation, United Kingdom
-
UCB Biopharma SRLCompletedNonradiographic Axial SpondyloarthritisUnited States, Belgium, Bulgaria, China, Czechia, France, Germany, Hungary, Japan, Poland, Spain, Turkey, United Kingdom
-
UCB Biopharma SRLActive, not recruitingPsoriatic ArthritisUnited States, Australia, Belgium, Canada, Czechia, France, Germany, Hungary, Italy, Japan, Poland, Russian Federation, Spain, United Kingdom